52North Overview

  • Year Founded
  • 2018

Year Founded

  • Status
  • Private

  • Employees
  • 28

Employees

  • Latest Deal Type
  • Later Stage VC

  • Latest Deal Amount
  • $4.3M

  • Investors
  • 29

52North General Information

Description

Operator of a finger-prick blood test and digital platform designed to improve safety and quality of life for cancer patients at risk of sepsis. The company's device is portable, easy to use, and provides a measure of a patient's neutrophil count and C-Reactive Protein (CRP) at home to identify the risk of neutropenic sepsis, the fatal side effect of chemotherapy, enabling patients to get access a reliable and cost-effective device that allows rapid management of the cancer condition.

Contact Information

Website
www.52north.health
Formerly Known As
NeutroCheck
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • IdeaSpace West, The Hauser Forum
  • 3 Charles Babbage Road
  • Cambridge CB3 0GT
  • England, United Kingdom
+44 07947
Primary Industry
Diagnostic Equipment
Other Industries
Other Healthcare Technology Systems
Vertical(s)
Digital Health, HealthTech, Life Sciences, Oncology
Corporate Office
  • IdeaSpace West, The Hauser Forum
  • 3 Charles Babbage Road
  • Cambridge CB3 0GT
  • England, United Kingdom
+44 07947

52North Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

52North Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
18. Later Stage VC 29-Sep-2026 $4.3M Completed Generating Revenue
17. Accelerator/Incubator 04-Sep-2025 Completed Generating Revenue
16. Grant 03-Dec-2024 Completed Generating Revenue
15. Accelerator/Incubator 02-Dec-2024 Completed Generating Revenue
14. Later Stage VC 14-Nov-2024 Completed Generating Revenue
13. Accelerator/Incubator 11-Jul-2023 Completed Generating Revenue
12. Accelerator/Incubator 02-Jun-2023 Completed Generating Revenue
11. Later Stage VC 10-Feb-2023 Completed Generating Revenue
10. Grant 23-Nov-2022 $1.63M $1.68M Completed Generating Revenue
9. Accelerator/Incubator 01-Jun-2022 $1.68M Completed Generating Revenue
To view 52North’s complete valuation and funding history, request access »

52North Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series Seed
Series Seed
Ordinary 65,086 $0.000108 $20.58 $20.58 1x $20.58 23.9%
To view 52North’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

52North Patents

  • 16

    Total Documents Applications and Grants

  • Total Patents Families

  • 10

    Granted

  • 3

    Pending

  • Expiring in next 12 mo

52North Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4412766-A1 Assay device for a suspension Pending 04-Oct-2021
GB-202114182-D0 Assay device for a suspension Active 04-Oct-2021
GB-2611355-A Assay device for a suspension Active 04-Oct-2021
GB-2611355-B Assay device for a suspension Active 04-Oct-2021
WO-2023057452-A1 Assay device for a suspension Inactive 04-Oct-2021 B01L3/5023
To view 52North’s complete patent history, request access »

52North Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

52North Investors (29)

Investor Name Investor Type Holding Investor Since Participating Rounds
Hargreave Hale AIM VCT 2 Corporation Minority
BioInnovation Institute Accelerator/Incubator
Deep Tech Lab - Quantum Accelerator/Incubator
National Institute for Health and Care Research Government
Nordic Mentor Network For Entrepreneurship Accelerator/Incubator
You’re viewing 5 of 29 investors. Get the full list »

Ready to get started?

Request a free trial

52North FAQs

  • When was 52North founded?

    52North was founded in 2018.

  • Where is 52North headquartered?

    52North is headquartered in Cambridge, United Kingdom.

  • What is the size of 52North?

    52North has 28 total employees.

  • What industry is 52North in?

    52North’s primary industry is Diagnostic Equipment.

  • Is 52North a private or public company?

    52North is a Private company.

  • What is 52North’s current revenue?

    The current revenue for 52North is .

  • How much funding has 52North raised over time?

    52North has raised $11.7M.

  • Who are 52North’s investors?

    Hargreave Hale AIM VCT 2, BioInnovation Institute, Deep Tech Lab - Quantum, National Institute for Health and Care Research, and Nordic Mentor Network For Entrepreneurship are 5 of 29 investors who have invested in 52North.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process